Biotech ImmVirX bucks VC "desert" to bank $15m, with $25m in sight
The company’s virus targets and kills colorectal, gastric or ovarian cancer cells before multiplying and releasing particles to destroy the remaining tumour.
Source: afr.com
Stay updated with breaking news from Venture Third Fund. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
The company’s virus targets and kills colorectal, gastric or ovarian cancer cells before multiplying and releasing particles to destroy the remaining tumour.